Efficacy and Safety of the CG-100 Intraluminal Bypass Device

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Rectal CancerRectal TumorRectal/Anal
Interventions
DEVICE

CG-100 intraluminal bypass device

a removable, temporary intraluminal bypass device, developed by Colospan, is designed to safely postpone the creation of a protective stoma until 10 days after surgery only for patients who need it (i.e. have a defect in the anastomosis)

PROCEDURE

Stoma

Primary protective ileostomy

Trial Locations (14)

10021

ACTIVE_NOT_RECRUITING

New York-Presbyterian / Weill Cornell Medical Center, New York

19107

ACTIVE_NOT_RECRUITING

Jefferson University Hospital, Philadelphia

20089

RECRUITING

Humanitas Research Hospital, Milan

40202

ACTIVE_NOT_RECRUITING

University of Louisville, Louisville

48202

ACTIVE_NOT_RECRUITING

Henry Ford Health System, Detroit

49100

WITHDRAWN

Rabin Medical Center, Petah Tikva

55455

ACTIVE_NOT_RECRUITING

East Bank Hospital - M Health Fairview University of Minnesota Medical Center, Minneapolis

80045

RECRUITING

Colorado University Anschutz Medical Campus, Aurora

84132

ACTIVE_NOT_RECRUITING

University of Utah Health, Salt Lake City

85025

RECRUITING

Soroka University Medical Center, Beersheba

92123

RECRUITING

Kaiser Permanente San Diego medical Center, San Diego

92868

RECRUITING

University of California Irvine, Orange

8250490

RECRUITING

Carmel Medical Center, Haifa

02906

ACTIVE_NOT_RECRUITING

Lifespan & Brown Surgical Associates, Providence

All Listed Sponsors
lead

Colospan Ltd.

INDUSTRY

NCT04184973 - Efficacy and Safety of the CG-100 Intraluminal Bypass Device | Biotech Hunter | Biotech Hunter